![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessHereditary and non-hereditary branches of family eligible for BRCA test: cancers in other sites
The analysis of relationships of BRCA alterations with cancer at sites other than breast/ovary may provide innovative information concerning BRCA pathogenic role and support additional clinical decisions. Aim ...
-
Article
Open AccessComment on ‘The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study’
-
Article
Open AccessExpression of base excision repair key factors and miR17 in familial and sporadic breast cancer
Understanding of BRCA1/2 interaction with the base excision repair (BER) pathway could improve therapy based on ‘synthetic lethality’, whose effectiveness is based on homologous recombination deficiency in cel...
-
Article
Open AccessPhase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer
The purpose of this study was to determine the maximum-tolerated dose of gemcitabine plus mitoxantrone in women with metastatic breast cancer (MBC) and to evaluate activity and toxicity of this combination in ...